Gene study spots clues to heart risk for statin patients

May 7, 2018, Vanderbilt University
Credit: CC0 Public Domain

A Vanderbilt-led research team has discovered genetic variations that increase the risk of heart attack even when patients are receiving a statin drug like Lipitor or Crestor to lower their blood cholesterol.

The finding, published by the journal Circulation, helps explain why some experience a or the need for coronary revascularization to open blocked heart arteries while taking statins. It suggests that drugs targeting the genetic variations could lower the heart risk in these patients.

The study demonstrates the power of genome-wide association studies and longitudinal electronic health records (EHRs) to find links between and disease, said the paper's first author, Wei-Qi Wei, MD, Ph.D., assistant professor of Biomedical Informatics in the Vanderbilt University School of Medicine.

Some of the patients were followed for for up to a decade after starting on their . The study found that the effect of the genetic variations or variants was independent of how much their cholesterol improved while taking statins.

"People with these genetic variants were at a higher risk for heart disease, even considering those who have ideal cholesterol levels on their statin," said Joshua Denny, MD, MS, Vice President of Personalized Medicine at Vanderbilt University Medical Center (VUMC) and the paper's corresponding author.

The researchers searched four sites in the Electronic Medical Records and Genomics (eMERGE) network, a nationwide consortium of experts, biorepositories and electronic medical record systems supported by the National Institutes of Health (NIH), including BioVU, VUMC's DNA databank.

They found 3,099 people who had experienced a heart attack or the need for revascularization while on statins, and compared them to 7,681 "control" patients on statins who did not experience heart events.

From this comparison, the researchers were able to identify seven genetic variations, called single nucleotide polymorphisms or SNPs, in the LPA locus of genes that were associated with these heart events in patients receiving statin treatment.

The LPA gene encodes apolipoprotein (a), a fatty protein that binds to low-density lipoprotein (LDL), the form of that is the target of statin drugs. High levels of bound LDL, called Lp(a) for short, is well known to be an independent risk factor for heart disease.

One of the SNPs was highly associated with an increased risk of heart events. When the researchers examined the full EHRs of 11,566 individuals who carried the SNP for more than 1,000 physical conditions, they found significantly higher rates of and heart attack but not of other diseases.

The approach, called a phenome-wide association study, was pioneered by Denny and his colleagues at Vanderbilt.

"The study highlights the need to consider targeting Lp(a) levels as an important independent factor to reduce cardiovascular risk in patients on therapy," Wei concluded.

Efforts to reduce Lp(a) levels using existing or new drugs could reduce events in the proportion of patients on statins who carry LPA variations, he added, although clinical trials would be needed to detect potential side effects and confirm the safety of any such treatment.

Explore further: Statins save lives of people with high levels of LDL cholesterol

More information: Wei-Qi Wei et al. LPAVariants are Associated with Residual Cardiovascular Risk in Patients Receiving Statins, Circulation (2018). DOI: 10.1161/CIRCULATIONAHA.117.031356

Related Stories

Statins save lives of people with high levels of LDL cholesterol

April 17, 2018
Cholesterol-lowering drugs are more likely to save thousands of additional lives when used in people with higher levels of LDL cholesterol, or "bad" cholesterol, according to a new study from the University of Iowa, published ...

Heart attack and stroke patients prescribed statin medication upon discharge have better outcomes

November 12, 2017
Patients with a prior history of heart attacks or stroke have better outcomes when cholesterol-lowering medications are used after they're discharged from the hospital, according to a new study from the Intermountain Medical ...

Quitting statins after stroke may raise risk of another stroke

August 2, 2017
Stroke patients who stopped taking statin drugs three to six months after a first ischemic stroke, the type caused by narrowed arteries, had a higher risk of a having another stroke within a year, according to new research ...

Statins associated with improved heart structure and function

May 26, 2017
Statins are associated with improved heart structure and function, according to research presented today at EuroCMR 2017. The benefits were above and beyond the cholesterol lowering effect of statins.

Poor response to cholesterol drugs may indicate blocked arteries

February 26, 2015
If your "bad" cholesterol level stays the same or increases after you take statin drugs, you may have more blocked arteries than people whose levels drop, according to research in the American Heart Association journal Arteriosclerosis, ...

Calcium in arteries influences heart attack risk

August 8, 2017
Patients without calcium buildup in the coronary arteries had significantly lower risk of future heart attack or stroke despite other high risk factors such as diabetes, high blood pressure, or bad cholesterol levels, new ...

Recommended for you

Surgery involving ultrasound energy found to treat high blood pressure

May 23, 2018
An operation that targets the nerves connected to the kidney has been found to significantly reduce blood pressure in patients with hypertension, according to the results of a clinical trial led in the UK by Queen Mary University ...

To have or not to have... your left atrial appendage closed

May 22, 2018
Each year in the U.S., more than 300,000 people have heart surgery. To reduce risk of stroke for their patients, surgeons often will close the left atrial appendage, which is a small sac in the left side of the heart where ...

Natural antioxidant bilirubin may improve cardiovascular health

May 18, 2018
Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology ...

New algorithm more accurately predicts life expectancy after heart failure

May 17, 2018
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more ...

New genes found that determine how the heart responds to exercise

May 17, 2018
A new study by researchers at Queen Mary University of London and University College London (UCL) has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.

Novel therapy inhibits complement to preserve neurons and reduce inflammation after stroke

May 16, 2018
A team of investigators at the Medical University of South Carolina (MUSC) has developed a novel therapy for ischemic (clot-caused) stroke and has shown in a preclinical model that it locally inhibits complement at and around ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.